1. Home
  2. EMF vs MDWD Comparison

EMF vs MDWD Comparison

Compare EMF & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$19.93

Market Cap

253.7M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.55

Market Cap

214.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMF
MDWD
Founded
1987
2000
Country
United States
Israel
Employees
N/A
121
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.7M
214.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
EMF
MDWD
Price
$19.93
$16.55
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
42.2K
104.1K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
6.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$48.92
Revenue Next Year
N/A
$35.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.58
$14.90
52 Week High
$21.20
$22.51

Technical Indicators

Market Signals
Indicator
EMF
MDWD
Relative Strength Index (RSI) 64.16 46.32
Support Level $16.24 $14.90
Resistance Level $20.44 $18.49
Average True Range (ATR) 0.43 0.70
MACD 0.18 -0.05
Stochastic Oscillator 91.97 25.77

Price Performance

Historical Comparison
EMF
MDWD

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: